Senior insider sale
Chief R&D Officer at NEKTAR THERAPEUTICS — senior position signals high conviction
$91.6K
2.93K shares
What this filing means
ZALEVSKY JONATHAN plans to sell 2.93K shares of NEKTAR THERAPEUTICS valued at approximately $91.6K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 9/4/2025ACC: 0001959173-25-005776
Officer· Chief R&D Officer
Since Oct 2019
2.93K
Shares to sell
$91.6K
Approx. market value
1.72K
Acquired (3 months)
1
Planned
2 completed
Securities Acquired — Last 3 Months4
Restricted Stock Vesting
Compensation
8/15/2024
586.00Restricted Stock Vesting
Compensation
5/15/2024
554.00Restricted Stock Vesting
Compensation
2/15/2024
443.00Restricted Stock Vesting
Compensation
11/15/2023
138.00Total acquired1.72K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
8/15/2024 | Restricted Stock Vesting Compensation | 586.00 | — |
5/15/2024 | Restricted Stock Vesting Compensation | 554.00 | — |
2/15/2024 | Restricted Stock Vesting Compensation | 443.00 | — |
11/15/2023 | Restricted Stock Vesting Compensation | 138.00 | — |
| Total | 1.72K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
485.00
Market value
$14.6K
9/2/2025
—Completed
Units to sell
725.00
Market value
$19.3K
8/19/2025
Planned — Approximate Date
NASDAQPlanned
Units to sell
1.72K
Market value
$57.7K
9/4/2025
Total
Units
2.93K
Value
$91.6K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
9/2/2025 | 485.00 | $14.6K | — | Completed |
8/19/2025 | 725.00 | $19.3K | — | Completed |
| Planned — Approximate Date | ||||
9/4/2025 | 1.72K | $57.7K | NASDAQ | Planned |
| Total | 2.93K | $91.6K | ||